CLPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CLPT is not a strong buy right now for a beginner, long-term investor with $50,000-$100,000 who is impatient and does not want to wait for a better entry. The stock has some fundamental growth and supportive analyst sentiment, but the current setup is mixed: technicals are neutral, options sentiment is bullish, and the latest quarter improved revenue, yet profitability remains negative and there is no clear catalyst from recent news. My direct view is hold rather than buy at this moment.
CLPT is in a neutral-to-mildly constructive technical position. RSI_6 is 56.1, which is neutral, and MACD histogram is positive at 0.111 but contracting, suggesting momentum is not accelerating. Moving averages are converging, which usually signals indecision rather than a clean trend. Price at 11.00 sits just below the pivot at 11.023, with resistance at 11.661 and 12.055 and support at 10.385 and 9.991. The recent stock trend model is modestly positive, but not strong enough to call this a clear breakout buy.
The latest quarter showed revenue growth of 33.96% year over year to $10.41M, and gross margin stayed strong at 61.52%. The company also cited around 13 partners under FDA expedited review and potential upside from gene therapy and ex-U.S. approvals, which supports long-term optionality. Options sentiment is also bullish, which adds a supportive trading bias.
There was no fresh news in the last week, so there is no immediate event-driven catalyst. Net income remains deeply negative at -$7.786M and EPS was -$0.27, so profitability is still not established. The company lowered 2026 guidance in recent analyst commentary, and hedge funds and insiders are both neutral with no notable buying trend. No recent congress trading data or influential figure trading was reported.
In 2025/Q4, ClearPoint Neuro delivered solid top-line growth with revenue up 33.96% year over year to $10.41M. Gross margin improved slightly to 61.52%, which is a healthy level. However, losses remain large, with net income at -$7.79M and EPS at -$0.27, so the company is still in a growth-investment phase rather than a profitable one. The latest quarter was seasonally Q4.
Analyst sentiment is constructive but somewhat mixed. On 2026-03-18, B. Riley raised the price target to $20 from $18 and kept a Buy rating, highlighting stronger revenue growth and de-risking in the gene therapy thesis. On 2026-03-05, the same firm cut the target from $28 to $18 after the FDA rejection in a related gene-therapy context, while still maintaining Buy. Net effect: pros see long-term upside and commercial optionality, but the recent target cuts show caution around regulatory and revenue visibility.
